澳优：25年国内业务承压但海外市场亮眼-20260204

Investment Rating - The report maintains an "Overweight" rating for the company with a target price of HKD 2.11 [6] Core Insights - The company is expected to generate revenue of RMB 7.48 billion in 2025, reflecting a year-on-year growth of 1.1%, and a net profit of RMB 240 million, also up 1.3% year-on-year. However, the second half of 2025 is projected to see a revenue decline of 3.4% and a net profit drop of 35.4% [1][2] - The domestic infant formula market is under pressure due to a decrease in newborn population, which fell by 162,000 to 7.92 million in 2025. This has led to a slight decline in sales within the domestic market [1][2] - The company's overseas business is expected to continue its strong revenue growth, with a reported 65.7% increase in overseas revenue in the first half of 2025. The company is optimistic about expanding into new markets in the Middle East and Southeast Asia [2][3] Revenue Summary - Domestic business is facing challenges, with no recovery in revenue for the goat and cow milk powder business expected in the second half of 2025. The company completed internal code adjustments in Q4 2025, which delayed the adjustment pace due to prior consumer stockpiling [2] - The overseas business is projected to maintain good revenue growth, driven by improved incentives for the overseas team and effective strategies like membership models [1][2] Profit Summary - The competitive landscape in the infant formula industry is intensifying, which is expected to pressure profit margins in the second half of 2025. The company anticipates a net profit of RMB 240 million for the year, with a profit margin under pressure in the second half [3] - Looking ahead to 2026, the company expects a potential recovery in profit margins as competition in the overseas market eases and the company optimizes its regional structure [3] Earnings Forecast and Valuation - The revenue forecast has been adjusted downwards due to ongoing domestic challenges, with expected revenue growth of 1.1%, 4.7%, and 4.6% for 2025-2027. The EPS estimates have also been reduced by 25%, 20%, and 17% for the same period [4] - The target price has been revised down to HKD 2.11, based on a 12x PE ratio for 2026, reflecting a decrease from the previous target of HKD 2.97 [4]